(secondQuint)An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access.

 Patients receive oral ganciclovir as maintenance.

 Patients enrolled at time of closure of enrollment will receive 2 months of study drug and undergo follow-up.

.

 An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access@highlight

To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.

